Beneficial Effects of Combining Nilotinib and Imatinib in Preclinical Models of BCR/ABL+ Leukemias Nilotinib and Imatinib Against Bcr-Abl+ Leukemia

Grant Support: J.D.G is supported by NIH grant CA66996, and a Specialized Center of Research Award from the Leukemia and Lymphoma Society. J.D.G. is also supported by NIH grants CA36167 and DK50654. P.W.M., J.M., and D.F. are employees of Novartis Pharma AG, Basel, Switzerland. J.D.G. has a financial interest with Novartis Pharma AG. Blood First Edition Paper, prepublished online October 26, 2006; DOI 10.1182/blood-2006-06-026377